US Federal House Bill HB1843

US Federal 2025-2026 Regular Session

• Introduced: 3/5/25
• Refer: 3/5/25

Caption

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Summary

HB1843 would amend the Federal Food, Drug, and Cosmetic Act to increase transparency in the FDA’s review of certain generic drug applications. The bill directs the Secretary of Health and Human Services, upon request from a generic drug applicant or prospective applicant, to tell the requester whether the proposed generic is qualitatively and quantitatively the same as the listed drug when the application involves certain inactive-ingredient requirements or an in vitro bioequivalence approach. If the FDA determines the product is not the same, the agency must identify which ingredient or ingredients cause the mismatch and disclose any quantitative deviation. The bill also limits the FDA’s ability to reverse a prior determination that a proposed generic is the same as the listed drug, except in narrow circumstances such as a change in the listed drug’s formulation tied to safety or effectiveness, or a written correction of an identified error. It further requires HHS to issue draft guidance within one year explaining how the agency will make these sameness determinations, including how it evaluates pH adjusters, and to provide a public comment period before finalizing the guidance. The statutory changes would take effect immediately upon enactment, even if the guidance is still pending.

Impact

If enacted, the bill would amend section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act, adding a new transparency and disclosure framework for abbreviated new drug applications (ANDAs). It would require FDA to provide more detailed pre-application or in-review feedback to generic drug sponsors, constrain post-determination changes, and create a formal guidance obligation for HHS. The practical effect would be to give generic manufacturers more certainty about formulation requirements and potential deficiencies, while also making FDA’s review process more explicit and predictable.

Sentiment

Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the measure appears to be framed as a technical, pro-transparency reform rather than a partisan or controversial policy change. Its stated purpose is to improve clarity in the generic drug approval process, which generally suggests support from stakeholders seeking faster, more predictable generic development. No vote history or transcript evidence is provided showing opposition or amendment activity.

Contention

The main potential point of contention is the balance between transparency for generic drug applicants and FDA’s discretion and confidentiality in the review process. The bill expressly overrides section 301(j) confidentiality limits for the required disclosures, which could raise concerns about proprietary information and agency workflow. Another possible issue is the restriction on the FDA’s ability to rescind a sameness determination after an application is submitted, which may be viewed by some as limiting regulatory flexibility, while supporters would likely argue it prevents uncertainty and inconsistent review outcomes.